Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11801240 Combination therapies and uses thereof

Overview Structured Data Issues Contributors Activity

Is a

Date Filed

October 5, 2018

Date of Patent

October 31, 2023

Patent Application Number

16754083

Patent Citations

US Patent 8217149 Anti-PD-L1 antibodies, compositions and articles of manufacture

US Patent 8436185 Pharmaceutically acceptable salts of 2-{4-[(3

US Patent 8728474 Immunopotentiative composition

US Patent 8779108 Targeted binding agents against B7-H1

US Patent 8952136 Antibodies to human programmed death receptor PD-1

US Patent 9624298 Anti-PD-L1 antibodies and uses thereof

US Patent 9815897 Antibodies directed against programmed death-1 (PD-1)

US Patent 9707302 Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer

US Patent 10738117 Antibodies directed against programmed death-1 (PD-1)

US Patent 7595048 Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1

•••

Patent Inventor Names

Zebin Wang

Yinghui Zhou

Keith W. Mikule

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Primary Examiner

Raymond J. Henley, III

CPC Code

Find more entities like US Patent 11801240 Combination therapies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool